gdc
FDA NewsFollicular LymphomaNewsworthy

Aliqopa the Newest Treatment Approved for Relapsed Follicular Lymphoma


December 2017 Vol 3 No 6 – December 18, 2017

On September 14, 2017, the FDA approved Aliqopa (copanlisib; from Bayer HealthCare) for the treatment of adults with relapsed follicular lymphoma who have received ≥2 previous systemic therapies.

“For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments. Options are limited for these patients and today’s approval provides an additional choice for treatment, filling an unmet need for them,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Aliqopa was based on a clinical trial showing improved response to therapy with this drug. Serious side effects with Aliqopa include infections, high blood sugar and blood pressure, inflammation of lung tissue, neutropenia, and severe skin reactions. Women who are breastfeeding should avoid this drug.

Recommended For You
Breast CancerNewsworthy
Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.
Breast CancerNewsworthyWeb Exclusives
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
LeukemiaLymphomaNewsworthy
Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers
The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
FDA NewsLiver CancerNewsworthy
Stivarga and Opdivo Newest Treatments for Liver Cancer
In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here